CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 32 enrolled
Drug / intervention
Cefdinir for oral suspension 250 mg/5mL +1 moredrug
Likely dose
Cefdinir for oral suspension 250 mg/5mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00834574
NCT00834574Phase 1Completed
CompareCT.gov

A Relative Bioavailability Study of Cefdinir for Oral Suspension 250 mg/5mL Under Fasting Conditions

Teva Pharmaceuticals USA·interventional·Posted Feb 3, 2009·Updated Aug 20, 2024

In Brief

A Phase 1 clinical trial evaluating Cefdinir for oral suspension 250 mg/5mL and OMNICEF® for oral suspension 250 mg/5mL for Healthy. Completed, enrolled 32 participants across 2 sites.

Detailed Summary

The objective of this study is to compare the relative bioavailability of cefdinir for oral suspension 250 mg/5mL (manufactured and distributed by TEVA Pharmaceuticals USA) with that of OMNICEF® for oral suspension, 250 mg/5mL (Abbott) in healthy, adult, non-smoking subjects under fasting conditions.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 3, 2009
Enrollment StartFeb 1, 2005
Primary CompletionMar 1, 2005
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 17.4 years ago

Interventions

Cefdinir for oral suspension 250 mg/5mLdrug

1 x 250 mg/5mL, single dose fasting

OMNICEF® for oral suspension 250 mg/5mLdrug

1 x 250 mg/5mL, single dose fasting